Bioblast Pharma Ltd. (ORPN)

18.50
0.09 0.48
NASDAQ : Health Technology
Prev Close 18.59
Open 19.44
Day Low/High 18.31 / 19.44
52 Wk Low/High 6.19 / 20.48
Volume 18.44K
Avg Volume 162.30K
Exchange NASDAQ
Shares Outstanding 420.00K
Market Cap 4.83M
EPS -14.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioBlast Scant Data Links Drug to Improved Swallowing in Patients

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.

BioBlast Pharma Augments Leadership Team

BioBlast Pharma Augments Leadership Team

Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer

BioBlast Pharma Augments Leadership Team And Establishes U.S. Headquarters In New Haven, Connecticut

BioBlast Pharma Augments Leadership Team And Establishes U.S. Headquarters In New Haven, Connecticut

Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer

Market News: Bio Blast Pharma, Micron Technology, Nike

Market News: Bio Blast Pharma, Micron Technology, Nike

The stock markets fluctuated and ended the trading session lower except the Dow Jones Industrial Average (DJIA), up 0.32%. Sign up for our free newsletter Companies in the semiconductor industry expe...

BioBlast Announces The Start Of A Phase 3 Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD)

BioBlast Announces The Start Of A Phase 3 Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD)

New Pivotal Study Reflects Positive Signals Reported From the Current HOPEMD Study, Which Will Be Closed Out at 25 Patients